Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

BACKGROUND: The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding cetuximab to FOLFOX or FOLFIRI increased efficacy in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Folprecht, Gunnar, Hamann, Susanne, Schütte, Katharina, Trarbach, Tanja, Stoehlmacher-Williams, Jan, Ehninger, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223588/
https://www.ncbi.nlm.nih.gov/pubmed/25038824
http://dx.doi.org/10.1186/1471-2407-14-521

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223588/
https://www.ncbi.nlm.nih.gov/pubmed/25038824
http://dx.doi.org/10.1186/1471-2407-14-521

Ejemplares similares